Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s stock price fell 0.4% on Thursday . The stock traded as low as $0.05 and last traded at $0.05, 1,469,419 shares traded hands during mid-day trading. A decline of 61% from the average session volume of 3,748,524 shares. The stock had previously closed at $0.05.
The firm has a 50 day moving average of $0.05 and a two-hundred day moving average of $0.04.
Pharmacyte Biotech Company Profile (OTCMKTS:PMCB)
PharmaCyte Biotech, Inc, a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.
Recommended Story: What are the benefits of a balanced fund?
Receive News & Ratings for Pharmacyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmacyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.